Promising Therapies for Sjogren's Dr. Yuz Yusof discusses abstracts 1634 at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/8iSDMKtKwa https://t.co/QCYTnpYKFN

ICYMI: SpA Sleuths: The Case of Undiagnosed IBD As rheumatologists, we are medical detectives investigating complex and often elusive autoimmune and inflammatory conditions https://t.co/dE0NLXKDvT https://t.co/DalUXRf3MB

CBT or Naltrexone in Fibromyalgia https://t.co/9SGRbY97oD https://t.co/wN2cMuqgHa

Expert consensus(ASAS) prefers SpondyloArthritis(axSpA) as preferred over "ankylosing spondylitis" (historic but no longer appropriate based on MRI research showing this is more than SI disease). AS radiographic axSpA(r-axSpA) can be used interchangeably https://t.co/jvT3lQFaPq https://t.co/WRNrbfjK1S

Danish study compared 106K adults w/ major osteoporotic fracture (hip, vertebrae, wrist, humerus) vs 1+ mill controls & found Mortality highest 30d following 1st index hip Fx (HR 10.98 women; & HR 16.40 men). Pneumonia most common cause of mortality https://t.co/0D7ynN4f5L https://t.co/qX61cgq1SL

Hemophagocytic Lymphohistiocytosis in Still's disease Dr. Bella Mehta discusses abstract 1143, presented at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/AFoKm6kT86 https://t.co/dLTjTOdbmv

Watch: Non-TNFi b/tsDMARDs vs. TNFi in RA-ILD https://t.co/fOz4jH58r9 https://t.co/jSHnsZscPg

Cardiology 101 for the Rheumatologist Dr. Janet Pope reports on a cardiology session presented a 2023 ACR Convergence in San Diego, CA https://t.co/0cS8JVneIG https://t.co/6SIPx6WmqX

FDA Warning on CAR-T Cell Therapy The FDA issued a safety alert on CAR-T cell immunotherapies; noting reports of T-cell malignancies (CAR-positive lymphoma) arising in patients treated with BCMA- or CD19-directed autologous CAR T cell immunotherapies. https://t.co/1OiMWJMskz https://t.co/8i8LFMcb1s

Full read BMJ ovverview of PMR - PMR Clinically recognized 1957 - Is it a uniquie vs overlap entity - Is there subclinical GCA in PMR? - Is PMR for PCPs? https://t.co/0BKGdt5Kxf https://t.co/sfAZoYyVan

ICYMI: How early is early in PsA? Guidelines for the management of PsA recommend the early referral of patients with the suspected condition for early assessment and treatment. https://t.co/AAZegiV6OL https://t.co/v5jIsPjX0c

Subtype of dermatomyositis is positive for Melanoma differentiation-associated protein 5 (MDA5) antibody. This poor prognosis subtype has distinctive rashes, rapidly progressive interstitial lung disease, lymphopenia &elevated ferritin levels https://t.co/FJjdO27cQQ https://t.co/gis2aWOLa7